Agenus Inc. (AGEN)

1.4800 0.0000 (0.00%) As of 12:47PM EDT. Market open.

Agenus Inc.

3 Forbes Road
Lexington, MA 02421-7305
United States
781 674 4400
https://www.agenusbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 533

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Garo H. Armen Ph.D.	Founder, Exec. Chairman & CEO	1.28M	380.18k	1953
Ms. Christine M. Klaskin	VP of Fin., Principal Financial Officer & Principal Accounting Officer	360.51k	52.17k	1966
Dr. Steven J. O'Day M.D., Ph.D.	Chief Medical Officer	1.44M	N/A	1962
Dr. Jennifer S. Buell Ph.D.	Pres & CEO of MiNK Therapeutics	917.25k	N/A	1975
Craig Winter	Chief Information Officer	N/A	N/A	N/A
Mr. Zack Armen	Head of Investor Relations	N/A	N/A	N/A
Ms. Robin E. Abrams J.D.	Chief Legal Officer	N/A	N/A	1964
Regina Grebla Ph.D.	VP of Investor Relations & Communications	N/A	N/A	N/A
Ms. Tracy Mazza Clemente	Chief People Officer	N/A	N/A	N/A
John Castle	Head of Translational Medicine & Bioinformatics	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Agenus Inc.’s ISS Governance QualityScore as of March 1, 2023 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.